Eli Lilly & Co. vs. Sionna Therapeutics, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| LLY | SION | |
|---|---|---|
| Market Cap | $1.06 trillion | $203.46 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-97,383,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | SION | |
|---|---|---|
| P/E Ratio | 41.35 | — |
| Price / Book | 31.20 | 0.77 |
| Price / Sales | 13.27 | — |
SION leads on 1 of 1 valuation factors.
Profitability
| LLY | SION | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | -36.64% |
LLY leads on 1 of 1 profitability factors.
Risk & Sentiment
| LLY | SION | |
|---|---|---|
| Short Interest | 1.29% | 1.39% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SION overview, SION financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.